MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia

AI Briefing

• – Minjuvi (tafasitamab) has been approved in Australia for adults with relapsed or refractory follicular lymphoma.
• – It is the first chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved.
• – Approved in combination with rituximab and lenalidomide.